Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 116

1.

Minimal residual disease monitoring in neuroblastoma patients based on the expression of a set of real-time RT-PCR markers in tumor-initiating cells.

Hartomo TB, Kozaki A, Hasegawa D, Van Huyen Pham T, Yamamoto N, Saitoh A, Ishida T, Kawasaki K, Kosaka Y, Ohashi H, Yamamoto T, Morikawa S, Hirase S, Kubokawa I, Mori T, Yanai T, Hayakawa A, Takeshima Y, Iijima K, Matsuo M, Nishio H, Nishimura N.

Oncol Rep. 2013 Apr;29(4):1629-36. doi: 10.3892/or.2013.2286.

PMID:
23417100
2.

Differential expression of minimal residual disease markers in peripheral blood and bone marrow samples from high-risk neuroblastoma patients.

Yamamoto N, Kozaki A, Hartomo TB, Yanai T, Hasegawa D, Kawasaki K, Kosaka Y, Matsuo M, Hirase S, Mori T, Hayakawa A, Iijima K, Nishio H, Nishimura N.

Oncol Lett. 2015 Nov;10(5):3228-3232.

3.

Detecting minimal residual disease in neuroblastoma: the superiority of a panel of real-time quantitative PCR markers.

Stutterheim J, Gerritsen A, Zappeij-Kannegieter L, Yalcin B, Dee R, van Noesel MM, Berthold F, Versteeg R, Caron HN, van der Schoot CE, Tytgat GA.

Clin Chem. 2009 Jul;55(7):1316-26. doi: 10.1373/clinchem.2008.117945.

4.

PHOX2B is a novel and specific marker for minimal residual disease testing in neuroblastoma.

Stutterheim J, Gerritsen A, Zappeij-Kannegieter L, Kleijn I, Dee R, Hooft L, van Noesel MM, Bierings M, Berthold F, Versteeg R, Caron HN, van der Schoot CE, Tytgat GA.

J Clin Oncol. 2008 Nov 20;26(33):5443-9. doi: 10.1200/JCO.2007.13.6531.

PMID:
18838715
5.

Early detection of tumor relapse/regrowth by consecutive minimal residual disease monitoring in high-risk neuroblastoma patients.

Hirase S, Saitoh A, Hartomo TB, Kozaki A, Yanai T, Hasegawa D, Kawasaki K, Kosaka Y, Matsuo M, Yamamoto N, Mori T, Hayakawa A, Iijima K, Nishio H, Nishimura N.

Oncol Lett. 2016 Aug;12(2):1119-1123.

6.

Stability of PCR targets for monitoring minimal residual disease in neuroblastoma.

Stutterheim J, Zappeij-Kannegieter L, Ora I, van Sluis PG, Bras J, den Ouden E, Versteeg R, Caron HN, van der Schoot CE, Tytgat GA.

J Mol Diagn. 2012 Mar-Apr;14(2):168-75. doi: 10.1016/j.jmoldx.2011.12.002.

PMID:
22251610
7.

Whole-genome sequencing identifies patient-specific DNA minimal residual disease markers in neuroblastoma.

van Wezel EM, Zwijnenburg D, Zappeij-Kannegieter L, Bus E, van Noesel MM, Molenaar JJ, Versteeg R, Fiocco M, Caron HN, van der Schoot CE, Koster J, Tytgat GA.

J Mol Diagn. 2015 Jan;17(1):43-52. doi: 10.1016/j.jmoldx.2014.09.005.

PMID:
25445214
8.

Outcome prediction by molecular detection of minimal residual disease in bone marrow for advanced neuroblastoma.

Horibe K, Fukuda M, Miyajima Y, Matsumoto K, Kondo M, Inaba J, Miyashita Y.

Med Pediatr Oncol. 2001 Jan;36(1):203-4.

PMID:
11464885
9.

Exploiting gene expression profiling to identify novel minimal residual disease markers of neuroblastoma.

Cheung IY, Feng Y, Gerald W, Cheung NK.

Clin Cancer Res. 2008 Nov 1;14(21):7020-7. doi: 10.1158/1078-0432.CCR-08-0541.

10.

Minimal residual disease in neuroblastoma: to GAGE or not to GAGE.

Oltra S, Martínez F, Orellana C, Grau E, Fernández JM, Cañete A, Castel V.

Oncol Res. 2004;14(6):291-5.

PMID:
15206491
11.

Multiple target molecular monitoring of bone marrow and peripheral blood samples from patients with localized neuroblastoma and healthy donors.

Corrias MV, Haupt R, Carlini B, Cappelli E, Giardino S, Tripodi G, Tonini GP, Garaventa A, Pistoia V, Pistorio A.

Pediatr Blood Cancer. 2012 Jan;58(1):43-9. doi: 10.1002/pbc.22960.

PMID:
21254375
12.

Clinical application of minimal residual neuroblastoma cell detection by reverse transcriptase-polymerase chain reaction.

Kuroda T, Saeki M, Nakano M, Mizutani S.

J Pediatr Surg. 1997 Jan;32(1):69-72.

PMID:
9021573
13.

Methylated RASSF1a is the first specific DNA marker for minimal residual disease testing in neuroblastoma.

Stutterheim J, Ichou FA, den Ouden E, Versteeg R, Caron HN, Tytgat GA, van der Schoot CE.

Clin Cancer Res. 2012 Feb 1;18(3):808-14. doi: 10.1158/1078-0432.CCR-11-0849.

14.

Disease outcome may be predicted by molecular detection of minimal residual disease in bone marrow in advanced neuroblastoma: a pilot study.

Fukuda M, Miyajima Y, Miyashita Y, Horibe K.

J Pediatr Hematol Oncol. 2001 Jan;23(1):10-3.

PMID:
11196262
15.

Impact of minimal residual disease detection prior to autologous stem cell transplantation for post-transplant outcome in high risk neuroblastoma.

Bochennek K, Esser R, Lehrnbecher T, Glienke W, Wehner S, Erben S, Soerensen J, Schwabe D, Bader P, Klingebiel T, Koehl U.

Klin Padiatr. 2012 Apr;224(3):139-42. doi: 10.1055/s-0031-1301334.

PMID:
22377741
16.

The doublecortin gene, a new molecular marker to detect minimal residual disease in neuroblastoma.

Oltra S, Martinez F, Orellana C, Grau E, Fernandez JM, Cañete A, Castel V.

Diagn Mol Pathol. 2005 Mar;14(1):53-7.

PMID:
15714065
17.

Potential application of ELAVL4 real-time quantitative reverse transcription-PCR for detection of disseminated neuroblastoma cells.

Swerts K, De Moerloose B, Dhooge C, Vandesompele J, Hoyoux C, Beiske K, Benoit Y, Laureys G, Philippé J.

Clin Chem. 2006 Mar;52(3):438-45.

18.

The prognostic value of fast molecular response of marrow disease in patients aged over 1 year with stage 4 neuroblastoma.

Stutterheim J, Zappeij-Kannegieter L, Versteeg R, Caron HN, van der Schoot CE, Tytgat GA.

Eur J Cancer. 2011 May;47(8):1193-202. doi: 10.1016/j.ejca.2011.02.003.

19.

Minimal residual disease levels in bone marrow and peripheral blood are comparable in children with T cell acute lymphoblastic leukemia (ALL), but not in precursor-B-ALL.

van der Velden VH, Jacobs DC, Wijkhuijs AJ, Comans-Bitter WM, Willemse MJ, Hählen K, Kamps WA, van Wering ER, van Dongen JJ.

Leukemia. 2002 Aug;16(8):1432-6.

20.

Minimal residual disease detection in autologous stem cell grafts from patients with high risk neuroblastoma.

van Wezel EM, Stutterheim J, Vree F, Zappeij-Kannegieter L, Decarolis B, Hero B, Berthold F, Schumacher-Kuckelkorn R, Simon T, Fiocco M, Voermans C, van Noesel MM, Caron HN, van der Schoot CE, Tytgat GA; GPOH MRD Study Group..

Pediatr Blood Cancer. 2015 Aug;62(8):1368-73. doi: 10.1002/pbc.25507.

PMID:
25939774
Items per page

Supplemental Content

Support Center